Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Amsterdam  >  Galapagos NV    GLPG   BE0003818359

GALAPAGOS NV

(GLPG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations
Communiqués de presse de la société GALAPAGOS NV
11/23GALAPAGOS : Selvita to acquire Fidelta from Galapagos
AQ
11/23GALAPAGOS : Selvita to acquire Fidelta from Galapagos
AQ
11/09GALAPAGOS : First patient dosed with GLPG3667 in psoriasis patient Phase 1b tria..
AQ
11/09GALAPAGOS : First patient dosed with GLPG3667 in psoriasis patient Phase 1b tria..
AQ
11/09First patient dosed with GLPG3667 in psoriasis patient Phase 1b trial
GL
11/09OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent ..
AQ
11/05GALAPAGOS : OncoArendi and Galapagos enter into exclusive collaboration on chiti..
AQ
11/05GALAPAGOS : OncoArendi and Galapagos enter into exclusive collaboration on chiti..
AQ
11/05OncoArendi and Galapagos enter into exclusive collaboration on chitinase inhi..
GL
11/05GALAPAGOS : reports Q3 2020 results
AQ
11/05GALAPAGOS : reports Q3 2020 results
AQ
11/05Galapagos reports Q3 2020 results
GL
11/03GILEAD SCIENCES : European Medicines Agency Validates Marketing Application for ..
AQ
11/02GALAPAGOS : European Medicines Agency Validates Marketing Application for Filgot..
BU
11/02GALAPAGOS : European  medicines  agency  validates  marketing  application  for ..
AQ
11/02GALAPAGOS : European  medicines  agency  validates  marketing  application  for ..
AQ
11/02European  medicines  agency  validates  marketing  application  for  filgotin..
GL
10/27GALAPAGOS : rsquo; R&D Roundtable showcases Toledo program
AQ
10/27GALAPAGOS : rsquo; R&D Roundtable showcases Toledo program
AQ
10/27Galapagos' R&D Roundtable showcases Toledo program
GL
10/16GALAPAGOS : And servier report topline results for roccella phase 2 clinical tri..
AQ
10/16Oxurion NV Business Update, Q3 2020
AQ
10/15GALAPAGOS : and Servier report topline results for ROCCELLA Phase 2 clinical tri..
AQ
10/15GALAPAGOS : and Servier report topline results for ROCCELLA Phase 2 clinical tri..
AQ
10/15Galapagos and Servier report topline results for ROCCELLA Phase 2 clinical tr..
GL
10/14Oxurion NV appoints Tom Graney, CFA as Chief Financial Officer
AQ
10/13GILEAD SCIENCES INC. : - Phase 2b/3 Trial Shows Efficacy of Filgotinib for the I..
AQ
10/12GALAPAGOS : Phase 2b/3 trial shows efficacy of filgotinib for the induction and ..
AQ
10/12GALAPAGOS : Phase 2b/3 trial shows efficacy of filgotinib for the induction and ..
AQ
10/12GALAPAGOS : Phase 2b/3 Trial Shows Efficacy of Filgotinib for the Induction and ..
BU
10/12Phase 2b/3 trial shows efficacy of filgotinib for the induction and maintenan..
GL
10/09Invitation OXURION R&D Investor Day, Virtual 15 October 2020 at 5.30pm CET/ 1..
AQ
09/30Oxurion NV to Present New Pre-Clinical Data on THR-687 at EURETINA 2020 Virtu..
AQ
09/30GALAPAGOS : announces first dosing with Toledo compound GLPG3970 in psoriasis tr..
AQ
09/29GALAPAGOS : announces first dosing with Toledo compound GLPG3970 in psoriasis tr..
AQ
09/29GALAPAGOS : announces first dosing with Toledo compound GLPG3970 in psoriasis tr..
AQ
09/29Galapagos announces first dosing with Toledo compound GLPG3970 in psoriasis ..
GL
09/28Gilead Sciences, Inc. - Jyseleca Approved in Japan for Rheumatoid Arthritis
AQ
09/28GILEAD SCIENCES : European Commission Grants Marketing Authorization for Jyselec..
AQ
09/25GALAPAGOS : European  commission  grants  marketing  authorization for jyseleca®..
AQ
09/25GALAPAGOS : European  commission  grants  marketing  authorization for jyseleca®..
AQ
09/25GALAPAGOS : European Commission Grants Marketing Authorization for Jyseleca® ..
BU
09/25European  commission  grants  marketing  authorization for jyseleca® (filgoti..
GL
09/25CORRECTION : Jyseleca® (filgotinib) approved in Japan for rheumatoid arthritis
GL
09/25CORRECTION : Jyseleca® (filgotinib) approved in Japan for rheumatoid arthritis
AQ
09/25GALAPAGOS : Jyseleca® (filgotinib) approved in Japan for rheumatoid arthritis
AQ
09/25Jyseleca® (filgotinib) approved in Japan for rheumatoid arthritis
GL
09/18GALAPAGOS : increases share capital through subscription right exercises
AQ
09/18GALAPAGOS : increases share capital through subscription right exercises
AQ
09/18Galapagos increases share capital through subscription right exercises
GL
09/18OXURION : Business Update, H1 2020
AQ
09/15Oxurion NV to Present at H.C. Wainwright & Co 22nd Annual Global Investment C..
AQ
09/10GALAPAGOS : Primary endpoint achieved with ziritaxestat  in NOVESA trial in syst..
AQ
09/10GALAPAGOS : Primary endpoint achieved with ziritaxestat  in NOVESA trial in syst..
AQ
09/10Primary endpoint achieved with ziritaxestat  in NOVESA trial in systemic scl..
GL
09/02Oxurion NV Reports First Patient Dosed in Phase 2 study evaluating THR-149 fo..
AQ
08/26Galapagos to present new insights in IPF and related clinical developments at..
GL
08/18Galapagos announces that Gilead received a complete response letter for filgo..
GL
08/12Scipher Medicine and Galapagos sign collaboration in inflammatory bowel disea..
GL
08/06GALAPAGOS : H1 Report 2020
PU
08/06Galapagos reports solid H1 2020 progress
GL
07/27GILEAD SCIENCES : and Galapagos Announce Positive European CHMP Opinion for Jyse..
AQ
07/24Gilead  and  galapagos  announce  positive  european  chmp  opinion  for  jys..
GL
07/24GALAPAGOS : Gilead and Galapagos Announce Positive European CHMP Opinion for Jys..
BU
06/08GILEAD SCIENCES : New Analyses of Phase 2 EQUATOR Clinical Program Support Durab..
AQ
06/05GALAPAGOS : New Analyses of Phase 2 EQUATOR Clinical Program Support Durable Eff..
BU
06/05New analyses of phase 2 equator clinical program support durable ef..
GL
06/04GALAPAGOS : Filgotinib Demonstrates Durable Efficacy and Consistent Safety Profi..
BU
06/04Filgotinib demonstrates durable efficacy and consistent safety profile..
GL
05/28Galapagos increases share capital through subscription right exercises
GL
05/20GALAPAGOS : Gilead and Galapagos Announce Positive Topline Results of Phase 2b/3..
BU
05/20Gilead and galapagos announce positive topline results of phase 2b/3..
GL
05/11GALAPAGOS : Written questions
PU
05/07GALAPAGOS : Q1 Report 2020 pdf
PU
05/07On track for clinical read-outs and commercial readiness in 2020
GL
1  2  3  4  5  6Next
Upcoming event on GALAPAGOS NV